Nivaquine B en es it fr

Nivaquine B Brand names, Nivaquine B Analogs

Nivaquine B Brand Names Mixture

  • No information avaliable

Nivaquine B Chemical_Formula


Nivaquine B RX_link

Nivaquine B fda sheet

Nivaquine_B FDA

Nivaquine B msds (material safety sheet)

Nivaquine_B MSDS

Nivaquine B Synthesis Reference

No information avaliable

Nivaquine B Molecular Weight

319.872 g/mol

Nivaquine B Melting Point

289 oC

Nivaquine B H2O Solubility

10.6 mg/L

Nivaquine B State


Nivaquine B LogP


Nivaquine B Dosage Forms


Nivaquine B Indication

For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis

Nivaquine B Pharmacology

Chloroquine is the prototype anti malarial drug, most widely used to treat all types of malaria except for disease caused by chloroquine resistant Plasmodium falciparum. It is highly effective against erythrocytic forms of Plasmodium vivax, Plasmodium ovale and Plasmodium malariae, sensitive strains of Plasmodium falciparum and gametocytes of Plasmodium vivax. Being alkaline, the drug reaches high concentration within the food vacuoles of the parasite and raises its pH. It is found to induce rapid clumping of the pigment. Chloroquine inhibits the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. It may also interfere with the biosynthesis of nucleic acids.

Nivaquine B Absorption

Completely absorbed from gastrointestinal tract

Nivaquine B side effects and Toxicity

No information avaliable

Nivaquine B Patient Information


Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.

In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.

Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.

Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.

Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.

Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.

Follow Rxlist link and link for detailed patient information.

Nivaquine B Organisms Affected